Arix Bioscience
Overview
Arix Bioscience is a global venture capital firm that invests in and builds breakthrough biotechnology companies focused on cutting-edge advances in life sciences.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Sorriso Pharmaceuticals | Dec 2021 | Series A | Lead |
| Depixus | Dec 2021 | Series A | Co-investor |
| Ensoma | May 2023 | Series B Extension | Co-investor |
| Evommune | Jun 2023 | Series B | Lead |
| Artios Pharma | Jul 2021 | Series C | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Arix Bioscience based?
Arix Bioscience is headquartered in London, United Kingdom.
When was Arix Bioscience founded?
Arix Bioscience was founded in 2015.
How many portfolio companies does Arix Bioscience have?
Arix Bioscience has 8 portfolio companies in Caplight's dataset.
What are some companies in Arix Bioscience's portfolio?
Portfolio companies visible on Caplight include Sorriso Pharmaceuticals, Depixus, Ensoma, Evommune, Artios Pharma.
What was Arix Bioscience's most recent investment shown here?
Arix Bioscience's most recent investment in this portfolio sample was in Evommune in 2023.
What sectors does Arix Bioscience focus on?
Arix Bioscience focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Arix Bioscience focus on?
Arix Bioscience typically invests at the Mid stage.
What is Arix Bioscience's AUM?
Arix Bioscience's assets under management are estimated between $284.0M and $284.0M.